biotech, fantom is not short...trust me. His anger at leadership and the lack of execution by this team is warranted. We just bounced off the 52-week low today. Volume has dried up...we will see where sales are. 60+ countries...I wouldn't highlight that fact unless there was any revenue/significant revenue coming from these countries.
I'm long 9 years and a lot of shares. The US trial is my final rodeo with this company.
News 
Market Data 
Discover 
